6 years of historical data (2019–2024) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
The Oncology Institute, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $219M | $23M | $150M | $133M | $646M | $638M | — |
| Enterprise Value | $292M | $97M | $237M | $227M | $532M | $644M | — |
| P/E Ratio → | -4.07 | — | — | — | — | — | — |
| P/S Ratio | 0.56 | 0.06 | 0.46 | 0.53 | 3.18 | 3.40 | — |
| P/B Ratio | 60.43 | 6.46 | 2.64 | 1.08 | 6.20 | 22.72 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 1256.83 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.25 | 0.73 | 0.90 | 2.62 | 3.44 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
The Oncology Institute, Inc. earns an operating margin of -15.3%. Operating margins have expanded from -32.5% to -15.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -213.4% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 13.7% | 13.7% | 18.4% | 20.6% | 20.1% | 19.7% | 19.3% |
| Operating Margin | -15.3% | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% | -1.7% |
| Net Profit Margin | -16.4% | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% | -2.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -213.4% | -213.4% | -92.2% | 0.1% | -16.5% | -40.7% | -9.5% |
| ROA | -33.9% | -33.9% | -35.3% | 0.1% | -8.1% | -22.9% | -6.8% |
| ROIC | -40.9% | -40.9% | -32.0% | -59.3% | -285.7% | -16.7% | -5.0% |
| ROCE | -40.8% | -40.8% | -37.9% | -40.4% | -43.5% | -19.7% | -5.8% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $73M ($123M total debt minus $50M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 34.31 | 34.31 | 2.10 | 0.88 | 0.00 | 0.42 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 20.47 | 1.51 | 0.76 | -1.10 | 0.21 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | -8.23 |
| Debt / FCF | — | — | — | — | — | — | -1.01 |
| Interest Coverage | -8.02 | -8.02 | -11.36 | -20.08 | -143.31 | -23.62 | -783.63 |
Short-term solvency ratios and asset-utilisation metrics
The Oncology Institute, Inc.'s current ratio of 2.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.39x to 2.15x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.15 | 2.15 | 4.12 | 4.39 | 5.17 | 1.04 | 1.60 |
| Quick Ratio | 1.96 | 1.96 | 3.73 | 4.08 | 4.95 | 0.89 | 1.32 |
| Cash Ratio | 0.95 | 0.95 | 2.38 | 2.48 | 3.84 | 0.21 | 0.18 |
| Asset Turnover | — | 2.28 | 1.55 | 0.96 | 1.00 | 2.85 | 2.61 |
| Inventory Turnover | 33.81 | 33.81 | 19.35 | 21.64 | 25.19 | 34.60 | 32.26 |
| Days Sales Outstanding | — | 45.17 | 48.31 | 58.45 | 38.20 | 33.59 | 34.61 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
The Oncology Institute, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.7% | 6.8% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $75M | $74M | $81M | $66M | $59M | $64M |
Compare TOI with 3 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| TOIYou | $219M | -4.1 | — | — | 13.7% | -15.3% | -213.4% | -40.9% | — |
| FMS | $14B | 11.8 | 6.3 | — | 25.6% | 9.3% | 6.5% | 5.6% | 3.3 |
| DVA | $10B | 17.2 | 9.1 | 8.0 | 27.0% | 14.7% | 46.0% | 10.5% | 5.5 |
| CCM | $167M | -0.0 | — | — | -20.6% | -138.6% | -18.3% | -7.7% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how TOI stacks up against sector leader Fresenius Medical Care AG & Co. KGaA.
Start ComparisonThe Oncology Institute, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
The Oncology Institute, Inc.'s return on equity (ROE) is -213.4%. The historical average is -62.0%.
Based on historical data, The Oncology Institute, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
The Oncology Institute, Inc. has 13.7% gross margin and -15.3% operating margin.